Shradha Samuel, MD
Vascular Surgery · Lincoln, NENPI 1922528207
Payments from drug & device makers
What this record shows
This record is dominated by grants: $6,666 of the $9,427 with a category attached, or 70.7%. Medtronic accounts for 82.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $5,066 and has fallen 94.2% since, to $292 in 2025.
Across 34 payments — averaging $277.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- W. L. Gore & Associates, Inc.$943
- Integra Lifesciences Corporation$177
- Penumbra, Inc.$158
- Endologix LLC$121
- Cook Medical LLC$74
- plus $153 from 7 others
What the payments were for
- Grants$6,66671%
- Food & beverage$1,89120%
- Education$8709%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 12 | $7,801 |
| W. L. Gore & Associates, Inc. | 8 | $943 |
| Integra Lifesciences Corporation | 2 | $177 |
| Penumbra, Inc. | 1 | $158 |
| Endologix LLC | 1 | $121 |
| Cook Medical LLC | 3 | $74 |
| Amgen | 1 | $36 |
| Abbott | 1 | $29 |
| Altathera Pharmaceuticals LLC | 1 | $25 |
| Davol Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Cordis US CORP. | 1 | $14 |
| Haemonetics Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,427 in reported general payments places this provider in the 70th percentile of 35 vascular surgery providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 20 | $14,387 |
| ClopidogrelClopidogrel Bisulfate | 18 | $203 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Lincoln
- Sara HargreavesLincoln$17K
- Alexis DavisLincoln$6K
- Kallie RobertsLincoln$3K
- Heidi HansenLincoln$3K
- Allie SohnLincoln$2K
- Steven TyndallLincoln$351
- Sarah OngstadLincoln$279
- Robert PitschLincoln$206
- Matthew GoettschLincoln$71
- John ParkOmaha$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.